09:37 AM EST - Marvel Biosciences Corp : Announces that its lead drug candidate MB-204 demonstrated a 400% increase in the survival rate of animals being treated by high doses of chemotherapy treatment, cis-platinum. Cis-platinum has potentially catastrophic side effects including kidney and nerve damage, cognitive dysfunction and hearing loss. The risk of nephrotoxicity in patients taking cis-platinum is between 20% and 35% and leads to death. "When we treated animals with MB-204, we saw an increase in their survival rate from between 20% and 80% while they were being given a high-dose course of cis-platinum," said Dr. Mark Williams, Chief Science Officer of Marvel. "Our data, suggests that Marvel's MB-204 could be an adjunct therapy to cis-platinum treatment as it can protect patients from long-term kidney damage, nerve damage and cognitive dysfunction. This could significantly help oncologists and improve patient outcomes in the treatment of many forms of cancer." Marvel Biosciences Corp
shares V.MRVL are trading up one cent at $0.17.
